Reinhart Harald's Form 4 filing
Zai Lab Ltd (ZLAB) · filed Jan 3, 2024
- Accession no.
- 0000905148-24-000061
- Filed
- Jan 3, 2024
- Trade date
- Jan 1-3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $125.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reinhart HaraldCIK 0001835824 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 1, 2024 | American Depositary Shares | MOption exerciseAcquired | +17,548 | –F3 | – | 50,863 | Direct | |
| Jan 3, 2024 | American Depositary Shares | SSaleDisposed | −4,803 | $26.12 | −$125,454.36 | 46,060 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 1, 2024 | American Depositary Shares | AGrant or awardAcquired | +17,548 | $0.00 | $0 | 17,548 | Direct | |
| Jan 1, 2024 | American Depositary Shares | MOption exerciseDisposed | −17,548 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Each PSU represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases